GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...
Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback